West Pharmaceutical Services, Inc. Reports Third Quarter 2026 Financial Results

West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, up 8.7%, with organic growth of 11.9%. Diluted EPS rose 57.3% to $3.02, while adjusted diluted EPS increased 35.7% to $2.66. The company repurchased $231 million of stock during the quarter, bringing year-to-date repurchases to $685 million; year-to-date operating cash flow was $403 million and capital expenditures were $125 million.